Barr Laboratories, Inc. v. Thompson’s Empirical Analysis

Citation profile

2 federal appellate · 13 district ·

Most-quoted passages

The sentences later courts lift from this opinion, ranked by how many decisions quote each — the parts of the opinion doing the work. These counts are smaller than the citation total above because most of the 16 citing decisions cite the case generally; a passage count includes only decisions quoting that exact language verbatim.

1. “(I) that the required patent information relating to such patent has not been filed; (II) that such patent has expired; (III) that the patent will expire on a particular date; (IV) that such patent is invalid or will not be infringed upon by the drug for which approval'is sought.”

   3 later decisions quote this exact passage · from the majority
   e.g. 355 F. Supp. 2d 111 - Teva Pharmaceuticals, Industries, Ltd. v. Food & Drug Administration · 332 F. Supp. 2d 106 - Mylan Laboratories, Inc. v. Thompson

2. “Under the Chevron framework, `[i]f ... "Congress has directly spoken to the precise question at issue, we must give effect to Congress's unambiguously expressed intent but [i]f the statute is silent or ambiguous with respect to the specific issue, we ask whether the agency's position rests on a permissible construction of the statute.”

   1 later decision quote this exact passage · from the majority
   e.g. Mylan Laboratories, Inc. v. Thompson

3. “`the period during which an [ANDA] may not be approved ... shall be extended by a period of six months after the date the patent expires,'”

   1 later decision quote this exact passage · from the majority
   e.g. Mylan Laboratories, Inc. v. Thompson